Lilly’s Mirikizumab Hits All Marks In First Phase III Study For UC

 
• By Joseph Haas
  
Lilly gets positive Phase III data for its anti-IL-23 candidate in ulcerative colitis
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D